STAT2 Is Required for TLR-Induced Murine Dendritic Cell Activation and Cross-Presentation
Overview
Authors
Affiliations
TLR-stimulated cross-presentation by conventional dendritic cells (cDCs) is important in host defense and antitumor immunity. We recently reported that cDCs lacking the type I IFN signaling molecule STAT2 are impaired in cross-presenting tumor Ags to CD8(+) T cells. To investigate how STAT2 affects cross-presentation, we determined its requirements for dendritic cell activation. In this study, we report that STAT2 is essential for the activation of murine female cDCs upon TLR3, -4, -7, and -9 stimulation. In response to various TLR ligands, Stat2(-/-) cDCs displayed reduced expression of costimulatory molecules and type I IFN-stimulated genes. The cDC responses to exogenous IFN-α that we evaluated required STAT2 activation, indicating that the canonical STAT1-STAT2 heterodimers are the primary signaling transducers of type I IFNs in cDCs. Interestingly, LPS-induced production of IL-12 was STAT2 and type I IFN receptor (IFNAR) dependent, whereas LPS-induced production of TNF-α and IL-6 was STAT2 and IFNAR independent, suggesting a specific role of the IFNAR-STAT2 axis in the stimulation of proinflammatory cytokines by LPS in cDCs. In contrast, R848- and CpG-induced cytokine production was less influenced by the IFNAR-STAT2 axis. Short kinetics and IFNAR blockade studies showed that STAT2 main function is to transduce signals triggered by autocrine type I IFNs. Importantly, Stat2(-/-) cDCs were deficient in cross-presenting to CD8(+) T cells in vitro upon IFN-α, CpG, and LPS stimulation, and also in cross-priming and licensing cytotoxic T cell killers in vivo. We conclude that STAT2 plays a critical role in TLR-induced dendritic cell activation and cross-presentation, and thus is vital in host defense.
STAT signaling pathways in immune cells and their associated mechanisms in cancer pathogenesis.
Sohrabi S, Alipour S, Ghahramanipour Z, Masoumi J, Baradaran B Bioimpacts. 2025; 15:30030.
PMID: 39963570 PMC: 11830145. DOI: 10.34172/bi.30030.
Novel genetically engineered mouse models for clear cell renal cell carcinoma.
van der Mijn J, Laursen K, Fu L, Khani F, Dow L, Nowak D Sci Rep. 2023; 13(1):8246.
PMID: 37217526 PMC: 10203127. DOI: 10.1038/s41598-023-35106-7.
Godoy-Tena G, Barmada A, Morante-Palacios O, de la Calle-Fabregat C, Martins-Ferreira R, Ferrete-Bonastre A Genome Med. 2022; 14(1):134.
PMID: 36443794 PMC: 9706884. DOI: 10.1186/s13073-022-01137-4.
Canar J, Darling K, Dadey R, Gamero A Cytokine. 2022; 161:156081.
PMID: 36327541 PMC: 9720715. DOI: 10.1016/j.cyto.2022.156081.
Abnormalities of the type I interferon signaling pathway in lupus autoimmunity.
Gallucci S, Meka S, Gamero A Cytokine. 2021; 146:155633.
PMID: 34340046 PMC: 8475157. DOI: 10.1016/j.cyto.2021.155633.